Prosecution Insights
Prosecution Insights
9 pending office actions • 7 art units • 7 examiners • 0 of 9 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (22%) |
| §112 only | 2 (22%) |
| Double-patenting only | 1 (11%) |
| Multi-statute (no §101) | 2 (22%) |
| No statute on record | 2 (22%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HADDAD, MAHER M | 2 | 50.5% | +53.9% |
| OUSPENSKI, ILIA I | 2 | 77.5% | +20.4% |
| OGUNBIYI, OLUWATOSIN A | 1 | 63.6% | +41.6% |
| HOLLAND, PAUL J | 1 | 57.3% | +64.7% |
| LEE, YIE CHIA | 1 | 71.9% | +45.6% |
| BARRERA, IMMACULADA | 1 | 34.6% | +77.3% |
| SINGH, ANOOP KUMAR | 1 | 42.7% | +67.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18512687 | METHODS, CELLS & ORGANISMS | HOLLAND, PAUL J | 140d overdue |
| 18250716 | ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF | BARRERA, IMMACULADA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17727309 | ANTI-ICOS ANTIBODIES | OUSPENSKI, ILIA I | 204d overdue |
| 18512687 | METHODS, CELLS & ORGANISMS | HOLLAND, PAUL J | 140d overdue |
| 18284952 | THERAPEUTIC INHIBITORS OF GDF15 SIGNALLING | LEE, YIE CHIA | 23d overdue |
| 18162043 | Animal Models and Therapeutic Molecules | SINGH, ANOOP KUMAR | 3d overdue |
| 18364906 | ANTIBODIES, USES & METHODS | HADDAD, MAHER M | 7d |
| 17725228 | SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD | OUSPENSKI, ILIA I | 12d |
| 18459995 | ANTIBODIES, COMBINATIONS COMPRISING ANTIBODIES, BIOMARKERS, USES & METHODS | HADDAD, MAHER M | 26d |
| 18713540 | Antibodies for Use as Therapeutics Against Bacterial Infections | OGUNBIYI, OLUWATOSIN A | — |
| Art Unit | Apps |
|---|---|
| 1641 | 2 |
| 1644 | 2 |
| 1645 | 1 |
| 1656 | 1 |
| 1642 | 1 |
| 1671 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18713540 | Antibodies for Use as Therapeutics Against Bacterial Infections | OGUNBIYI, OLUWATOSIN A | 1645 | §112 | Non-Final OA | — | Pending | May 24, 2024 |
| 18512687 | METHODS, CELLS & ORGANISMS | HOLLAND, PAUL J | 1656 | §102§103Other | Final Rejection | 140d overdue | Pending | Nov 17, 2023 |
| 18284952 | THERAPEUTIC INHIBITORS OF GDF15 SIGNALLING | LEE, YIE CHIA | 1642 | §112 | Non-Final OA | 23d overdue | Pending | Sep 29, 2023 |
| 18459995 | ANTIBODIES, COMBINATIONS COMPRISING ANTIBODIES, BIOMARKERS, USES & METHODS | HADDAD, MAHER M | 1641 | §103 | Final Rejection | 26d | Pending | Sep 01, 2023 |
| 18364906 | ANTIBODIES, USES & METHODS | HADDAD, MAHER M | 1641 | Other | Final Rejection | 7d | Pending | Aug 03, 2023 |
| 18250716 | ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF | BARRERA, IMMACULADA | 1671 | §102§112 | Non-Final OA | — | Pending | Apr 26, 2023 |
| 18162043 | Animal Models and Therapeutic Molecules | SINGH, ANOOP KUMAR | 1632 | §103Other | Final Rejection | 3d overdue | Pending | Jan 31, 2023 |
| 17727309 | ANTI-ICOS ANTIBODIES | OUSPENSKI, ILIA I | 1644 | DP | Final Rejection | 204d overdue | Pending | Apr 22, 2022 |
| 17725228 | SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD | OUSPENSKI, ILIA I | 1644 | Other | Non-Final OA | 12d | Pending | Apr 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial